Table 1.
Estimated Metabolite Concentration ± SD Calculated by TARQUINa.
| Metabolite | Ependymoma (n = 4) | Medulloblastoma (n = 17) | Pilocytic Astrocytoma (n = 20) | P‐Value |
|---|---|---|---|---|
| Cit* | 0.96 ± 0.21 | 0.56 ± 0.31 | 0.47 ± 0.48 | 0.031 |
| Glc | 1.2 ± 0.27 | 2.3 ± 1.7 | 1.07 ± 1.06 | 0.073 |
| Gln | 1.69 ± 0.11 | 2.6 ± 1.53 | 2.2 ± 2.6 | 0.429 |
| Glth* | 1.12 ± 0.32 | 1.8 ± 0.8 | 0.66 ± 0.6 | <0.000 |
| Glu | 1.14 ± 0.94 | 2.4 ± 2.2 | 3.2 ± 2.3 | 0.055 |
| Gly* | 1.92 ± 0.5 | 3.7 ± 2.08 | 0.73 ± 0.76 | <0.000 |
| mIns | 4.53 ± 2.3 | 2.29 ± 1.66 | 1.94 ± 1.73 | 0.097 |
| Lac* | 1.39 ± 0.68 | 1.65 ± 1.7 | 0.65 ± 0.74 | 0.041 |
| Scyllo* | 0.008 ± 0.01 | 0.37 ± 0.47 | 0.05 ± 0.08 | 0.009 |
| Tau* | 0.6 ± 0.75 | 6.3 ± 4.1 | 1.07 ± 1.03 | <0.000 |
| tNAA* (tNAA = NAA + NAAG) | 0.53 ± 0.25 | 1.03 ± 0.44 | 1.37 ± 0.95 | 0.007 |
| tCho* | 1.69 ± 0.29 | 3.94 ± 1.74 | 1.4 ± 0.709 | <0.000 |
| tCr* | 1.69 ± 0.79 | 3.91 ± 1.5 | 2.29 ± 2.22 | 0.003 |
| tLM09 | 3.7 ± 1.4 | 4.94 ± 2.4 | 3.02 ± 1.87 | 0.084 |
| tLM13* | 21.4 ± 10.05 | 19.32 ± 13.01 | 7.8 ± 3.7 | <0.000 |
| tLM20 | 7.2 ± 1.8 | 7.53 ± 4.1 | 6.3 ± 3.4 | 0.444 |
Cit, citrate; Glc, glucose; Gln, glutamine; Glth, glutathione; Glu, glutamate; Gly, glycine; Lac, lactate; mIns, myo‐inositol; NAA,N‐acetylaspartate; NAAG,N‐Acetylaspartylglutamic acid; scyllo, scyllo‐inositol; SD, standard deviation; Tau, taurine; tNAA, total N‐acetylaspartate; tCho, total choline; tCr, total creatine; tLM09, lipids and macromolecules 0.9; tLM13, lipids and macromolecules 1.3; tLM20, lipids and macromolecules 2.0.
a
The P‐value of analysis of variance (calculated using Kruskal‐Wallis test with α = 0.05) is comparing ependymoma versus medullobastoma versus pilocytic astrocytoma.
*Metabolites with P‐values less than 0.05.